Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM) delivery platform is patented for all nonpsychoactive cannabinoids as well as for tetrahydrocannabinol (THC) and psychoactive cannabinoids. An article discussing the company reads, “Medical researchers have struggled to find ways to penetrate the blood brain barrier effectively to transport beneficial drugs for many years. This barrier exists to block toxic or otherwise dangerous substances from entering the brain and is formed by layers of microvascular endothelial cells inside blood vessels. Lexaria’s DehydraTECH(TM) drug delivery platform brings beneficial drugs to the brain faster. . . . In June 2019, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. This series built on the company’s original, independent, third-party laboratory in vitro lab experiments began in 2015, which showed utilization of the DehydraTECH drug-delivery platform increased the absorption levels of cannabidiol (CBD) in human intestinal cells by an impressive 499%. The results of the studies showed delivery of 1,937% more CBD into animal brain tissue after eight hours using the enhanced DehydraTECH technology in comparison with generic industry MCT coconut-oil formulations. Moreover, the animal studies using the enhanced formulation showed an 811% increase of CBD delivery into the blood in comparison with generic MCT coconut-oil formulations.”
To view the full article, visit http://nnw.fm/ziR1P
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.